About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 29 record(s)
Req # A-2023-000008
The most recent draft copy of the State of Per and Polyfluoroalkyl Substances (PFAS) Report being prepared by Health Canada.Organization: Health Canada
September 2023
Req # A-2021-001603
For the Abbreviated New Drug Submission underlying the generic submission under review containing the medicinal ingredient “trabectedin”, provide the cover letter from the drug sponsor.Organization: Health Canada
April 2022
Req # A-2021-001600
For the Abbreviated New Drug Submission underlying the generic submission under review containing the medicinal ingredient “trabectedin”, provide the proposed Certified Product Information Document.Organization: Health Canada
February 2022
Req # A-2021-001601
For the Abbreviated New Drug Submission underlying the generic submission under review containing the medicinal ingredient “trabectedin”, provide the “Batch Formula” (3.2.P.3.2).Organization: Health Canada
February 2022
Req # A-2021-001602
For the Abbreviated New Drug Submission underlying the generic submission under review containing the medicinal ingredient “trabectedin”, provide the “Description of Manufacturing Process and Process Controls” (3.2.P.3.3).Organization: Health Canada
February 2022
Req # A-2021-001605
For the Abbreviated New Drug Submission underlying the generic submission under review containing the medicinal ingredient “trabectedin”, provide the proposed Product Monograph.Organization: Health Canada
February 2022
Req # A-2021-00107
Provide 2020, 2021 lessons learned and BMD's/incident reports on Darlington unit 2 refurbishing and associated costs/cost overruns. Provide expected obstacles, challenges to encounter to encounter in refurbishing Darlington unit 3, 1 and 4 , including assessing plans, vendors, financial and safety risks.Organization: Canadian Nuclear Safety Commission
January 2022
Req # A-2021-00052
Provide a copy of the briefing note “Regan Dow v. Canadian Nuclear Safety Commission” It is dated 2021-06-30 Ref # 6596361.Organization: Canadian Nuclear Safety Commission
September 2021
Req # A-2021-00055
Provide the briefing note “Applying the Precautionary Principle in Canada Nuclear Safety Commission Decision-Making – February 26, 2020” It is dated 2021-05-06 Ref # 6241579.Organization: Canadian Nuclear Safety Commission
September 2021
Req # A-2020-00203
Please provide: 1) Copy [name withheld] Letter delivered on June 16, 2020, to the CNSC President. 2) Edoc Number of [name withheld], Lawyer, letter delivered, on June 16, 2020, 3) Copy of any email(s) sent to [name withheld], Lawyer by CNSC Staff.Organization: Canadian Nuclear Safety Commission
May 2021